CNS Pharmaceuticals Crescita futura

Future criteri di controllo 0/6

Si prevede che CNS Pharmaceuticals aumenterà gli utili e i ricavi rispettivamente del 54.7% e 86.4% all'anno, mentre si prevede che l'EPS crescerà del 68.5% all'anno.

Informazioni chiave

54.7%

Tasso di crescita degli utili

68.5%

Tasso di crescita dell'EPS

Pharmaceuticals crescita degli utili	23.9%
Tasso di crescita dei ricavi	86.4%
Rendimento futuro del capitale proprio	n/a
Copertura analitica	Low
Ultimo aggiornamento	15 Nov 2024

Aggiornamenti recenti sulla crescita futura

Recent updates

CNS Pharmaceuticals reports Q2 results

Aug 15

Here's Why We're A Bit Worried About CNS Pharmaceuticals' (NASDAQ:CNSP) Cash Burn Situation

Dec 04

CNS Pharmaceuticals sinks after pricing equity offering of $10M

Dec 23

Previsioni di crescita degli utili e dei ricavi

NasdaqCM:CNSP - Stime future degli analisti e dati finanziari passati (USD Millions )
Data	Ricavi	Guadagni	Flusso di cassa libero	Liquidità dell'operazione	Avg. Numero di analisti
12/31/2026	N/A	-21	N/A	N/A	1
12/31/2025	N/A	-16	N/A	N/A	1
12/31/2024	N/A	-13	N/A	N/A	1
9/30/2024	N/A	-17	-14	-14	N/A
6/30/2024	N/A	-16	-11	-11	N/A
3/31/2024	N/A	-17	-13	-13	N/A
12/31/2023	N/A	-19	-14	-14	N/A
9/30/2023	N/A	-19	-14	-14	N/A
6/30/2023	N/A	-18	-12	-12	N/A
3/31/2023	N/A	-17	-12	-12	N/A
12/31/2022	N/A	-15	-11	-11	N/A
9/30/2022	N/A	-13	-11	-11	N/A
6/30/2022	N/A	-14	-12	-12	N/A
3/31/2022	N/A	-14	-13	-13	N/A
12/31/2021	N/A	-14	-14	-14	N/A
9/30/2021	N/A	-14	-12	-12	N/A
6/30/2021	N/A	-12	-11	-11	N/A
3/31/2021	N/A	-11	-9	-9	N/A
12/31/2020	N/A	-9	-7	-7	N/A
9/30/2020	N/A	-9	-8	-8	N/A
6/30/2020	N/A	-8	-7	-7	N/A
3/31/2020	N/A	-6	-5	-5	N/A
12/31/2019	N/A	-4	-4	-4	N/A
9/30/2019	N/A	-8	-1	-1	N/A
6/30/2019	N/A	-7	-1	-1	N/A
3/31/2019	N/A	-7	-1	-1	N/A
12/31/2018	N/A	-7	-1	-1	N/A

Previsioni di crescita futura degli analisti

Guadagni vs tasso di risparmio: Si prevede che CNSP rimarrà non redditizia nei prossimi 3 anni.

Guadagni vs Mercato: Si prevede che CNSP rimarrà non redditizia nei prossimi 3 anni.

Guadagni ad alta crescita: Si prevede che CNSP rimarrà non redditizia nei prossimi 3 anni.

Ricavi vs Mercato: Si prevede che CNSP non avrà alcun fatturato il prossimo anno.

Ricavi ad alta crescita: Si prevede che CNSP non avrà alcun fatturato il prossimo anno.

Previsioni di crescita dell'utile per azione

Rendimento futuro del capitale proprio

ROE futuro: Dati insufficienti per determinare se il Return on Equity di CNSP è previsto essere elevato tra 3 anni

Scoprire le aziende in crescita

Analisi aziendale e situazione dei dati finanziari

Dati	Ultimo aggiornamento (ora UTC)
Analisi dell'azienda	2024/12/29 10:58
Prezzo dell'azione a fine giornata	2024/12/27 00:00
Guadagni	2024/09/30
Guadagni annuali	2023/12/31

Fonti dei dati

I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.

Pacchetto	Dati	Tempistica	Esempio Fonte USA ^*
Dati finanziari della società	10 anni	Conto economico Rendiconto finanziario Bilancio	Modulo SEC 10-K Modulo SEC 10-Q
Stime di consenso degli analisti	+3 anni	Previsioni finanziarie Obiettivi di prezzo degli analisti	Rapporti di ricerca degli analisti Blue Matrix
Prezzi di mercato	30 anni	Prezzi delle azioni Dividendi, scissioni e azioni	Dati di mercato ICE Modulo SEC S-1
Proprietà	10 anni	Top azionisti Insider trading	Modulo 4 SEC Modulo 13D SEC
Gestione	10 anni	Team di leadership Consiglio di amministrazione	Modulo SEC 10-K Modulo SEC DEF 14A
Sviluppi principali	10 anni	Annunci aziendali	Modulo 8-K SEC

^* esempio per i titoli statunitensi, per quelli non statunitensi si utilizzano forme e fonti normative equivalenti.

Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più , cliccate qui.

Modello di analisi e Snowflake

I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github; abbiamo anche guide su come utilizzare i nostri report e tutorial su Youtube.

Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.

Metriche di settore e industriali

Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su .

Fonti analitiche

CNS Pharmaceuticals, Inc. è coperta da 4 analisti. 1 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.

Analista	Istituzione
Matthew Cross	Alliance Global Partners
Bruce Jackson	Benchmark Company
Robert LeBoyer	Ladenburg Thalmann & Company

CNS Pharmaceuticals Crescita futura

Future criteri di controllo 0/6

Informazioni chiave

Aggiornamenti recenti sulla crescita futura

Price target increased to US$10.00

Recent updates

CNS Pharmaceuticals Receives Exception by Nasdaq to Regain Compliance with Minimum Bid Price Requirement

CNS Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $3 million.

CNS Pharmaceuticals Regains Compliance with Nasdaq Equity Requirement

CNS Pharmaceuticals, Inc. announced that it expects to receive funding from Cortice Biosciences Incorporated

CNS Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $5.2 million.

The Nasdaq Hearings Panel Grants the Requested Extension to CNS Pharmaceuticals Until August 12, 2024

CNS Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $1.98075 million.

CNS Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $1.98075 million.

CNS Pharmaceuticals, Inc. announced a financing transaction

CNS Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $1.3725 million.

New major risk - Share price stability

CNS Pharmaceuticals, Inc., Annual General Meeting, Apr 30, 2024

CNS Pharmaceuticals Receives Non-Compliance Letter Form Nasdaq

CNS Pharmaceuticals Provides Non-Compliance Update

CNS Pharmaceuticals, Inc. Appoints Amy Mahery to its Board of Directors

CNS Pharmaceuticals, Inc. has filed a Follow-on Equity Offering.

CNS Pharmaceuticals, Inc. Presents Updated Safety Data from Ongoing Potentially Pivotal Study Evaluating Berubicin in Advance of the Pre-Planned Interim Analysis of Efficacy

New major risk - Negative shareholders equity

CNS Pharmaceuticals, Inc. Opens 46 Clinical Trial Sites Across the U.S., Italy, France, Spain, and Switzerland

Cns Pharmaceuticals, Inc. Announces Enrollment of 200 Patients in Ongoing Potentially Pivotal Study of Berubicin with the Treatment of Glioblastoma Multiforme (Gbm)

CNS Pharmaceuticals Receives Letter from Nasdaq Regarding Non-Compliance with Minimum of $2.5 Million in Stockholders’ Equity Requirement Pursuant to Nasdaq’s Listing Rule 5550(b)(1)

CNS Pharmaceuticals, Inc., Annual General Meeting, Sep 14, 2023

CNS Pharmaceuticals, Inc., Annual General Meeting, Sep 14, 2023

CNS Pharmaceuticals, Inc. Provides Clinical Trial Update for Ongoing Potentially Pivotal Study with Berubicin for the Treatment of Glioblastoma Multiforme

Bettina M. Cockroft Joins CNS Pharmaceuticals, Inc.'s Board of Directors

CNS Pharmaceuticals Announces First Patient Enrolled in Spain in Ongoing Potentially Pivotal Global Trial Evaluating Berubicin for the Treatment of GBM

CNS Pharmaceuticals, Inc. Announces Investigator-Initiated Phase 1B/2 Trial to Be Conducted At the Pomeranian Medical University in Poland

Cns Pharmaceuticals, Inc. Appoints Faith Charles as Independent Member and as Chairperson of the Board of Directors

CNS Pharmaceuticals, Inc Announces Preliminary Results from Ongoing Potentially Pivotal Trial Evaluating Berubicin for the Treatment of Recurrent Glioblastoma Multiforme (GBM)

CNS Pharmaceuticals, Inc. has completed a Follow-on Equity Offering.

Insufficient new directors

CNS Pharmaceuticals, Inc. Announces Dosing of First Patient in Europe/France in Ongoing Potentially Pivotal Global Trial Evaluating Berubicin for the Treatment of GBM

CNS Pharmaceuticals, Inc. Announces Activation of First Clinical Trial Sites in Europe for Ongoing Potentially Pivotal Global Trial Evaluating Berubicin for the Treatment of GBM

CNS Pharmaceuticals, Inc. Provides A Clinical Update of Its Anti-Cancer Drug Candidates Currently in Development for the Treatment of Primary and Metastatic Brain and CNS Cancer

CNS Pharmaceuticals reports Q2 results

CNS Pharmaceuticals, Inc., Annual General Meeting, Jul 27, 2022

CNS Pharmaceuticals Inc. Receives Approval from U.S. FDA for Protocol Amendment to Ongoing Potentially Pivotal Global Trial Evaluating Berubicin for the Treatment of GBM

CNS Pharmaceuticals, Inc. Announces Presentation of Ongoing Potentially Pivotal Berubicin Clinical Trial Design at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting

Price target increased to US$10.00

Insufficient new directors

CNS Pharmaceuticals, Inc. Receives Approval from Competent Authority of Switzerland for Potentially Pivotal Study of Berubicin for the Treatment of Glioblastoma Multiforme

CNS Pharmaceuticals, Inc. announced that it expects to receive $11.500001 million in funding

Insufficient new directors

Here's Why We're A Bit Worried About CNS Pharmaceuticals' (NASDAQ:CNSP) Cash Burn Situation

CNS Pharmaceuticals, Inc. Receives Approval from Switzerland Ethics Committee for its Potentially Pivotal Study of Berubicin for the Treatment of Glioblastoma Multiforme

FDA Grants Fast Track Designation to CNS Pharmaceuticals, Inc. for Berubicin for the Treatment of Recurrent Glioblastoma Multiforme

CNS Pharmaceuticals Commences Patient Enrollment in Potentially Pivotal Study of Berubicin

CNS Pharmaceuticals Berubicin Trial is on Schedule to Commence in March 2021

WPD Pharmaceuticals and CNS Pharmaceuticals, Inc. Announces Berubicin Supply Agreement for the Upcoming Clinical Trials

WPD Pharmaceuticals and CNS Pharmaceuticals, Inc. Announce Positive Opinion of the Polish Central Ethics Committee for the WPD-201 Study and Central IRB Study Level Approval for the CNS-201 Study

New 90-day high: US$3.50

CNS Pharmaceuticals Announces It Has Been Featured in Syndicated Broadcast Covering Recent FDA Approval of IND Application

CNS Pharmaceuticals sinks after pricing equity offering of $10M

CNS Pharmaceuticals, Inc. Announces FDA Approval of IND Application for its Brain Cancer Drug Candidate Berubicin

New 90-day high: US$2.89

Previsioni di crescita degli utili e dei ricavi

Previsioni di crescita futura degli analisti

Previsioni di crescita dell'utile per azione

Rendimento futuro del capitale proprio

Scoprire le aziende in crescita

Analisi aziendale e situazione dei dati finanziari

Fonti dei dati

Modello di analisi e Snowflake

Metriche di settore e industriali

Fonti analitiche